A partial restriction on tests of an experimental and well-financed gene therapy for Duchenne muscular dystrophy (DMD) gave way to a full FDA clinical hold following a serious adverse reaction in the first patient dosed. The boy has since recovered. But shares of Solid Biosciences Inc. (NASDAQ:SLDB), which raised $133.7 million in a January IPO despite a then-partial hold on the candidate, SGT-001, fell 64.6 percent to $9.32 by Thursday's close.